Search

A recent study conducted at Shahid Beheshti University of Medical Sciences in Iran aimed to evaluate the knowledge, attitude, and practice of Iranian thalassemia major patients towards iron chelating agents (ICAs). The study involved 101 patients and found that a significant number of patients had poor knowledge about their medications. The research suggests that educational interventions are needed to improve patients' knowledge and practice regarding their medicines. This information is important for library patrons researching thalassemia and its treatment options. [Extracted from the article]

Keywords: Antidotes; Pharmaceuticals; Oxford; Europe; Hemolytic; Thalassemia; Psychosocial; Iron Overload; Psychological; United Kingdom; Quality of Life; Hydroxamic Acids; Chelation Therapy; Congenital Anemia; Hemoglobinopathies; Sickle Cell Anemia; Deferasirox Therapy; Drugs and Therapies; Health and Medicine; Risk and Prevention EN Antidotes Pharmaceuticals Oxford Europe Hemolytic Thalassemia Psychosocial Iron Overload Psychological United Kingdom Quality of Life Hydroxamic Acids Chelation Therapy Congenital Anemia Hemoglobinopathies Sickle Cell Anemia Deferasirox Therapy Drugs and Therapies Health and Medicine Risk and Prevention New research on Hematologic Diseases and Conditions - Sickle Cell Anemia is the subject of a report. Deferasirox versus deferoxamine We are uncertain whether or not deferasirox affects adherence to iron chelation therapy (three RCTs, unpooled, very low-certainty evidence), although medication adherence was high in all trials. [Extracted from the article]

A recent study conducted at Thammasat University in Thailand examined the prevalence of habitual snoring (HS) and its impact on quality of life in pediatric thalassemia patients. The study found that 48.2% of the patients reported snoring, with 19.9% experiencing HS. The prevalence of HS did not significantly differ between non-transfusion dependent thalassemia (NTDT) and transfusion dependent thalassemia (TDT) patients. Risk factors associated with HS included nasal congestion and male gender. Overall, the study concluded that thalassemia children generally exhibited a good quality of life, and the standard care provided for TDT patients may contribute to reducing nasopharyngeal narrowing. [Extracted from the article]

This document is a patent application for the use of EHMT2 inhibitors in treating or preventing various blood disorders. The inhibitors target a specific mechanism in cells and could potentially be effective in conditions such as anemia, thalassemia, leukemia, lymphoma, and sickle-cell disease. The application provides specific compounds that could be used as inhibitors and suggests that they can be used alone or in combination with other treatments. For more information, readers are directed to the full patent application. [Extracted from the article]

A recent study conducted in Telangana, India, aimed to determine the Isocitrate Dehydrogenase (IDH1) gene mutation and Alpha Thalassemia/Mental retardation X-linked (ATRX) mutation in gliomas through immunohistochemistry. The study found that IDH1 mutation was more common in diffuse fibrillary astrocytomas and anaplastic astrocytomas, while ATRX loss was predominantly seen in glioblastomas. The researchers concluded that IDH1 and ATRX are reliable prognostic markers for gliomas and that immunohistochemistry provides a practical method for categorizing gliomas. This research contributes to a better understanding of gliomas and may assist clinicians in achieving promising treatment outcomes. [Extracted from the article]

A study conducted at Prince Sattam bin Abdulaziz University has provided new insights into beta thalassemia, a rare disorder characterized by the appearance of hematopoietic elements outside the bone marrow or peripheral blood. The study describes a case of a 21-year-old man with beta thalassemia who experienced small bowel obstruction and portal hypertension due to extramedullary hematopoiesis (EMH). Surgery successfully resolved the clinical problems, and the patient was discharged home. This research contributes to our understanding of the manifestations and management of beta thalassemia. [Extracted from the article]

A recent study conducted by researchers at the University of Babylon in Iraq aimed to investigate the epidemiology of thalassemia in Babylon. The study involved 306 thalassemic patients and collected data on demographic characteristics, age at diagnosis, socio-economic status, family history, blood transfusions, chelation therapy, and serum ferritin levels. The results showed that thalassemia major was the most common type, and the majority of patients received regular blood transfusions. The study also found a high prevalence of complications and stunted growth in children under 10 years old. The researchers concluded that early diagnosis, regular transfusion programs, and comprehensive screening and counseling programs are necessary for managing thalassemia effectively. [Extracted from the article]

A recent study conducted by the Department of Ophthalmology aimed to evaluate retinal vascular changes in patients with sickle cell disease (SCD) and beta-thalassemia using optical coherence tomography angiography (OCT-A). The study included 98 patients with SCD, 75 patients with beta-thalassemia, and 100 healthy controls. The researchers found that all OCT-A parameters were significantly different in both patient groups compared to the controls, suggesting that OCT-A can be used to diagnose and monitor retinopathy in individuals with hemoglobinopathies. The study also found that OCT-A parameters are affected before the development of clinically detectable retinopathy. [Extracted from the article]

A recent study conducted at the University of Campania Luigi Vanvitelli in Naples, Italy explores the potential association between asthma and hemoglobinopathies such as thalassemia and sickle cell disease (SCD). The study found that asthma is more prevalent among thalassemia patients compared to the general population, with rates around 30%. Similarly, asthma frequently coexists with SCD, affecting approximately 20-48% of patients. The presence of asthma in SCD exacerbates respiratory symptoms and increases the risk of severe complications. The study suggests that chronic inflammation, oxidative stress, and immune dysregulation associated with hemoglobinopathies may contribute to the development of asthma. The researchers emphasize the importance of interdisciplinary collaboration among healthcare professionals to effectively manage this complex interplay and improve care and outcomes for affected individuals. [Extracted from the article]

A recent study from the University of Verona in Italy explores novel therapeutic approaches for thalassemias, sickle cell disease (SCD), and other red cell disorders. The researchers discuss the development of new pharmacologic agents and their potential targets in the treatment of these conditions. The study also highlights the potential for repurposing existing drugs to affect heme synthesis and potentially treat multiorgan diseases. The research concludes that these new therapeutic options have the potential to expand treatment options for patients with thalassemias, SCD, and other red cell disorders. [Extracted from the article]

Researchers at Complutense University Madrid have conducted a study on rare anemias in Spain using data from the REHem-AR registry. The study included 1,756 patients with haemoglobinopathies and rare anaemias, with sickle cell disease (SCD) being the most common condition. The study found that neonatal bloodspot screening was the most common method of diagnosing SCD, and vaso-occlusive crisis and acute chest syndrome were the most frequent complications. The researchers concluded that the REHem-AR registry is important for tracking the natural history of rare anaemias and determining treatment needs. [Extracted from the article]

A study conducted by researchers from Zabol University of Medical Sciences in Iran evaluated the level of liver enzymes and their relationship with ferritin and the frequency of blood transfusions in patients with thalassemia major, the most common hemolytic anemia in Iran and the world. The study found a significant increasing trend in the levels of AST, ALT, and ALP in thalassemic patients, with AST and ALT showing significant correlations with serum ferritin. Serum ferritin levels of more than 1625 mg/dl were found to predict abnormal liver enzymes with high sensitivity and specificity. The researchers suggest that serum ferritin, along with other factors, can be used as an index for assessing liver function in thalassemia patients. [Extracted from the article]

A recent study conducted at the American University of Beirut has provided new insights into thalassemia, a congenital anemia. The research highlights the impact of improved survival rates on the quality of life of adult patients with thalassemia, as well as the potential development of psychiatric and cognitive disorders. The study reviews available evidence on quality of life, mood disorders, and cognitive impairment in adult patients with thalassemia, drawing from the researchers' own experiences in treating patients. This research has been peer-reviewed and offers valuable information for individuals interested in understanding the impact of thalassemia on patients' well-being. [Extracted from the article]

Researchers at Southwest University in Chongqing, China have developed a clinical trait-imaging fusion model to predict the mutational status of alpha-thalassemia X-linked intellectual disability (ATRX) in high-grade astrocytoma patients. The model combines preoperative magnetic resonance imaging (MRI) radiomics and deep learning (DL) features with clinical variables. The fusion model showed excellent prediction performance, with an area under the curve of 0.969 in the training set, 0.956 in the validation set, and 0.949 in the test set. This model has the potential to help develop more effective treatment strategies for individuals with IDH-mutant high-grade astrocytoma. [Extracted from the article]

A recent study conducted by researchers at Ahvaz Jundishapur University of Medical Sciences in Iran aimed to evaluate the prevalence of alpha-thalassemia and glucose-6-phosphate dehydrogenase (G6PD) deficiency in sickle cell trait (SCT) patients and its effect on red blood cell parameters. The study analyzed 102 blood samples from children and teenagers with SCT and found that the prevalence of alpha-thalassemia, G6PD deficiency, and iron deficiency anemia in the sample was 18.63%, 13.72%, and 10.78% respectively. The researchers concluded that it is important to screen all SCT patients for G6PD deficiency to prevent exacerbation of their condition during unexpected events. [Extracted from the article]

A study conducted by Hanoi Medical University focused on the use of short tandem repeats (STRs) in preimplantation genetic diagnosis (PGD) for a-thalassemia, an autosomal recessive blood disorder. The study aimed to help couples at risk of having a child with a-thalassemia by facilitating the birth of healthy children. The researchers analyzed the DNA of 89 couples and their family members and carried out 91 cycles of PGD. The study found that the use of STR markers in PGD resulted in the birth of 36 healthy children and 17 ongoing pregnancies, demonstrating the feasibility and credibility of this method. [Extracted from the article]

A recent study conducted by researchers at the University of Peshawar in Pakistan explores the relationship between thalassemia, an inherited blood disorder, and depression. Thalassemia, which affects hemoglobin production, significantly impacts the quality of life and well-being of patients. The study, which involved 60 subjects aged 4 to 14 years, found a positive correlation between thalassemia and depression. The research highlights the need for further investigation into depression in thalassemia patients and suggests avenues for future research and therapeutic interventions. However, the study's scope is limited to a local hospital and faces challenges such as language barriers and cultural stigma. [Extracted from the article]

A recent study conducted by the University of Ferrara in Italy has shed light on the therapeutic relevance of inducing autophagy in b-thalassemia, a genetic disorder that affects the hematopoietic system. The study explores various experimental strategies for reducing excess free a-globin chains in b-thalassemia, including CRISPR-Cas9-based genome editing, induction of fetal hemoglobin (HbF), and the induction of the autophagic process. The researchers discuss the regulation of this process by the Unc-51-like kinase 1 (Ulk1) gene and its interplay with other factors. This research provides valuable insights into potential biomarkers and therapeutic targets for b-thalassemia. [Extracted from the article]

A recent study conducted by researchers at the University of Porto in Portugal explored the role of catalase (CAT), glutathione peroxidase (GPx), and peroxiredoxin 2 (Prx2) in counteracting the effects of oxidative stress in sickle cell anemia. The study found that these enzymes bind to the red blood cell (RBC) membrane and play a protective role against oxidative membrane injuries in healthy RBCs. However, the amount of enzyme linkage was found to be lower in sickle cell disease (SCD) patients, possibly due to structural changes induced by sickle hemoglobin. The findings suggest that the oxidative stress-induced changes and antioxidant response differ among different types of anemias, which may contribute to the variations in clinical patterns observed in these patients. [Extracted from the article]

A recent report from the Federal University of Minas Gerais (UFMG) in Brazil discusses the clinical, laboratory, and molecular characteristics of a group of children with hemoglobinopathy S/beta-thalassemia (HbSb-thal). The study identified 14 alleles of beta-thalassemia mutations and estimated the incidence of HbSb-thal in Minas Gerais to be 1 per 22,250 newborns. The research found that beta-thalassemia mutations were associated with various clinical and laboratory features, and children with HbSb+-intermediate phenotypes had a more severe profile compared to those with HbSb+-mild phenotypes. The study suggests that early identification of beta-thalassemia alleles can aid in the clinical management of affected children. [Extracted from the article]

A new study on beta thalassemia, conducted at University Hospital in Varna, Bulgaria, explores the correlation between beta-stiffness index (BSI) and atherogenic lipid indices as markers of subclinical atherosclerosis in patients with beta thalassemia major (BTM). The study found that young adults with BTM are at an increased risk of atherosclerosis, which can be easily detected through carotid ultrasound examination using BSI and atherogenic lipid indices. The research highlights the importance of monitoring vascular impairment in BTM patients due to the high risk of accelerated atherosclerosis. [Extracted from the article]

Researchers at Jining Medical University in China have made progress in understanding the relationship between Fanconi anemia (FA) and non-obstructive azoospermia (NOA), a condition characterized by spermatogenesis failure. The study found that FA gene mutations in male NOA patients can cause significant damage to male germ cells. The FA pathway, which is activated in the presence of DNA interstrand cross-links, plays a role in repairing DNA damage. The researchers hope that their findings will contribute to further clinical research and exploration of related genes. [Extracted from the article]

A recent study conducted at Hospital Universitario Oswaldo Cruz in Brazil examined the clinical and cytogenetic profile of patients with Fanconi anemia (FA) in the state of Pernambuco. FA is a rare autosomal recessive disease characterized by chromosomal instability and an increased risk of malignancy. The study analyzed 100 individuals referred from hematology and bone marrow transplant centers and identified 16 patients with FA. The primary clinical findings were cafe au lait spots and bone abnormalities, with most patients coming from specific regions in Pernambuco. The researchers concluded that these results are important for promoting early diagnosis and multidisciplinary treatment of FA. [Extracted from the article]

A recent report from the Center for Cancer Research discusses the interplay between a-thalassemia and b-hemoglobinopathies, which are important genetic factors in certain blood disorders. The report highlights the relationship between genotype and phenotype and explores potential therapies based on this understanding. The researchers emphasize the need for further investigation into the modulation of a-globin chains as a potential treatment for b-hemoglobinopathies. This research provides valuable insights into the field of hematology and offers potential avenues for future therapies. [Extracted from the article]

This document provides information about a clinical research study on the role of the Kruppel-like factor 1 (KLF1) gene mutation in beta-thalassemia, a type of congenital anemia. The study aims to recruit 100 patients with beta-thalassemia, both genders, and any age. The study will assess the impact of the KLF1 gene mutation on the severity of beta-thalassemia. The primary contact for the study is Mohamed Mahmoud, and the estimated completion date is December 2027. [Extracted from the article]

A recent study conducted by researchers at Oregon Health & Science University (OHSU) explored the effects of long-term combination therapy with metformin and oxymetholone on bone marrow failure in a mouse model of Fanconi anemia (FA). The researchers found that while oxymetholone treatment showed modest improvements in blood parameters, the combination of metformin and oxymetholone did not have a significant synergistic effect. However, gene expression analysis showed that metformin treatment partially normalized some of the expression changes caused by Fancd2 deletion. Importantly, no adverse effects were observed with the individual or combination therapies. The study suggests that androgen therapy is not contraindicated with concurrent metformin administration in clinical trials. [Extracted from the article]

A recent report from Shanghai Jiao Tong University in China discusses the findings of a pilot trial on modified lentiviral globin gene therapy for pediatric transfusion-dependent b-thalassemia. The trial involved two female children who were infused with a genetically modified cell product called BD211. The results showed successful engraftment of the modified cells, with no unexpected safety issues and both patients achieving transfusion independence for over 22 months. The study concludes that optimized lentiviral gene therapy may be a safe and effective treatment for b-thalassemia. [Extracted from the article]

A recent study conducted by researchers at the University of Indonesia highlights the psychological burden faced by pediatric patients with thalassemia major in Indonesia. Thalassemia is a hereditary blood disorder that leads to anemia. The chronic nature of the disease, along with physical changes and complications, increases the risk of mental disorders and cognitive impairment in these patients. The study emphasizes the importance of routine evaluation of mental health problems in order to detect and treat mental disorders early. A multidisciplinary approach that includes medical care, psychosocial support, and good transition care is recommended to improve the well-being and social integration of thalassemia patients. [Extracted from the article]

This document provides information about a clinical trial conducted by Regeneron Pharmaceuticals. The trial aims to evaluate the effectiveness of a drug called REGN7999 in patients with non-transfusion-dependent thalassemia (NTDT). The trial will involve the administration of REGN7999 or a placebo to participants in different dosage groups. The recruitment for the trial has not yet started, and it is estimated to enroll 95 participants with an estimated completion date of January 24, 2028. The trial is open to individuals of all genders between the ages of 18 and 60. The responsible party for the trial is Regeneron Pharmaceuticals, and they plan to share the data collected from the trial. [Extracted from the article]

A research study conducted at the First Affiliated Hospital of Guangxi Medical University in China has developed a novel algorithm to differentiate between mild to moderate thalassemia trait (TT) and iron deficiency anemia (IDA). These two conditions have similar clinical and laboratory features, making it challenging to distinguish between them. The algorithm, called the Thalassemia and IDA Discrimination Index (TIDI), showed high accuracy and diagnostic performance in distinguishing between TT and IDA. It also demonstrated good classification performance in distinguishing between different genotypes of TT and IDA. This algorithm can be a useful tool for the differential diagnosis of these conditions in the Guangxi region of China. [Extracted from the article]

A recent report from the University College of Medical Sciences in Delhi, India, discusses a rare case of moyamoya syndrome (MMS) in a child with beta-thalassemia trait. The 7-year-old boy presented with symptoms including right-sided monoparesis, focal seizures, and limb weakness. Further investigations revealed microcytic hypochromic anemia and the presence of beta-thalassemia trait. Imaging tests showed infarction in the cerebral arteries and collateral formation suggestive of moyamoya angiopathy. The child's condition improved with aspirin and supportive management. This case highlights the potential association between MMS and beta-thalassemia trait, which may only be diagnosed after the identification of moyamoya disease following a stroke. [Extracted from the article]

A recent study conducted by researchers at Tehran University of Medical Sciences in Iran investigated the prevalence of short stature in patients with thalassemia major. The study found that 32% of patients had short stature, which can lead to mental and social problems. The risk of short stature increased with age, with patients aged 10-11 and 27 years and older being at the highest risk. The researchers recommend monitoring for short stature starting at 5 years of age to prevent complications. [Extracted from the article]

A new study conducted at the Universite de Sousse in Tunisia focuses on hemoglobinopathies, which are genetic disorders affecting blood proteins. The study aimed to report the experience of newborn screening for hemoglobinopathy in Tunis. The researchers collected cord blood from 156 newborns and conducted hemoglobin exploration to screen for hemoglobinopathies. The findings revealed the presence of b-thalassemia and a-thalassemia in the population, with frequencies of 12% and 0.33% respectively. The study concludes that newborn screening can help diagnose different types of hemoglobinopathies, benefiting both the child's care and genetic counseling for parents. [Extracted from the article]

A recent study conducted by researchers from Walailak University in Thailand explored the association between thalassemia, hemoglobinopathies, vitamin D levels, and lipid profile in adults. The study involved 615 participants from the southern Thai population and utilized hemoglobin analysis and polymerase chain reaction-based methods to diagnose thalassemia and hemoglobinopathies. The findings revealed that individuals with thalassemia had a significantly lower frequency of lipid-lowering drug use and lower total cholesterol and low-density lipoprotein cholesterol levels compared to those without thalassemia. Additionally, the study found a high prevalence of hypovitaminosis D in carriers of thalassemia and/or hemoglobinopathies. However, the researchers noted that further investigation with a larger sample size is needed to confirm these associations, particularly in countries with a high prevalence of thalassemia. [Extracted from the article]

A recent study conducted at Children's Healthcare Atlanta explored the post-transfusion survival of red blood cells (RBCs) from donors with alpha-thalassemia trait in recipients with sickle cell disease (SCD). The researchers used biotin labeling to measure the survival of multiple donor RBC units post-transfusion. They found that RBCs from donors with alpha-thalassemia trait had accelerated clearance and increased surface phosphatidylserine compared to normal RBCs. However, further research is needed to determine the impact of thalassemia trait donors on transfusion efficacy. This study provides valuable insights into chronic transfusion therapy for SCD patients. [Extracted from the article]

A recent report from Christian Medical College and Hospital in Punjab, India highlights the importance of antenatal thalassemia screening and prenatal diagnosis in preventing the birth of thalassemia major children. The study found that out of 5,392 antenatal women counseled for beta thalassemia screening, 3.4% were detected to be heterozygous for thalassemia, and partner screening was advised for 7.1% of affected women. Prenatal diagnosis was performed in 19 risk couples, resulting in the detection of 3 affected fetuses. The research emphasizes the need for community-level awareness and the inclusion of thalassemia screening and prenatal diagnosis in the healthcare system. [Extracted from the article]

This document provides information about a Phase 1b clinical trial (NCT06408857) conducted by the Bill & Melinda Gates Medical Research Institute. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of a drug called MAM01 in adults, children, and special pediatric populations in Africa. The trial will be conducted in Kenya and Uganda and will test different doses of MAM01 through subcutaneous or intramuscular injections in healthy adults, older children, and infants, as well as in children and infants with medical conditions that increase their risk of malaria. The primary outcome measures include adverse events and abnormal laboratory results. The trial is not yet recruiting and is estimated to be completed in May 2026. [Extracted from the article]

According to a preprint abstract, researchers have conducted in utero hematopoietic stem cell transplantation (HSCT) for Fanconi Anemia (FA), a genetic disorder that leads to bone marrow failure and malignancies. FA can be cured postnatally through HSCT, but this requires chemotherapy and/or irradiation-based conditioning, which can have side effects. The researchers performed in utero HSCT in FA mouse models and observed successful engraftment of healthy donor cells, suggesting that in utero HSCT may be a safe and curative prenatal treatment for FA. This research has not yet been peer-reviewed. [Extracted from the article]

A new report from the First Affiliated Hospital of Guangxi Medical University in Nanning, China, discusses the development of a prediction model for secondary failure of platelet recovery (SFPR) in patients with b-thalassemia major (b-TM) after hematopoietic stem cell transplantation (HSCT). The researchers used a retrospective study to develop the prediction model, which was based on pretransplant serum ferritin, hepatomegaly, mycophenolate mofetil use, and posttransplant serum albumin. The model showed good predictive ability and may be used by clinicians to identify SFPR patients early and recommend effective preventive measures. This research provides valuable insights for the treatment and management of thalassemia patients undergoing HSCT. [Extracted from the article]

A recent study conducted in Baise, People's Republic of China, explored the effects of a multidisciplinary team (MDT) continuous care model on the psychological behavior and quality of life in children with beta-thalassemia major (beta-TM). The study involved 90 children with beta-TM who were hospitalized in the Department of Pediatrics at the Affiliated Hospital of Youjiang Medical University for Nationalities. The results showed that the MDT continuous care model effectively improved mental health, quality of life, and medical satisfaction in children with beta-TM. It also reduced the incidence of complications and improved prognosis. The study suggests that the MDT continuous care model should be widely applied in clinical settings. [Extracted from the article]

A recent study conducted in Haryana, India, focused on compound heterozygous sickle cell beta thalassemia, a condition that affects populations in low-income countries like India. The study found that elevated levels of Hemoglobin A2 (HbA2) are the primary indicator for identifying carriers of beta thalassemia. However, the study also noted that High Performance Liquid Chromatography (HPLC) can encounter challenges in confirming a final diagnosis when HbA2 and Hemoglobin S (HbS) levels fall outside the diagnostic range. The researchers concluded that diagnosing compound heterozygous hemoglobinopathies can be challenging, and it is important to carefully differentiate between sickle cell anemia and beta thalassemia, although the prognosis is better than thalassemia major or sickle cell anemia. [Extracted from the article]

A recent report from the University of Ferrara in Italy discusses the findings of a study on thalassemia, a genetic blood disorder. The study focused on the role of a protein called a-hemoglobin-stabilizing protein (AHSP) in preventing the harmful effects of excess a-globin chains in the erythroid cells of thalassemia patients. The researchers found that treatment with sirolimus, a medication, increased the expression of AHSP in erythroid precursor cells (ErPCs) isolated from thalassemia patients. This study suggests that AHSP expression could be an important endpoint in clinical trials involving sirolimus. [Extracted from the article]

A case study conducted by researchers at Cukurova University in Adana, Turkey, explores the rare coexistence of sickle-cell thalassemia and lymphoma in a 37-year-old patient. The study highlights the diagnostic and therapeutic challenges posed by this dual diagnosis and emphasizes the need for patient-centered care. The researchers found multiple abnormal findings in the patient, including hyperdense gallbladder stones, increased reticular density in the mesenteric root, and nodular lesions in the thyroid gland. The study contributes to the limited literature on the intersection of hemoglobinopathies and lymphoma, providing insights into the management of these rare comorbid conditions. [Extracted from the article]

A recent preprint abstract discusses a potential treatment for alpha-thalassemia, a genetic blood disorder. The researchers developed a genome editing strategy using Cas9/AAV6 to insert a functional alpha-globin gene into patient-derived hematopoietic stem and progenitor cells. They also incorporated a truncated erythropoietin receptor transgene, which increased the production of red blood cells and normal hemoglobin. This approach shows promise for a curative treatment for alpha-thalassemia, offering an alternative to hematopoietic stem cell transplantation. However, it is important to note that this research has not yet undergone peer review. [Extracted from the article]

A study conducted at Quanzhou Women's and Children's Hospital in China has identified a rare form of thalassemia called Hemoglobin (Hb) Lepore-Boston-Washington in four unrelated Chinese families. Traditional thalassemia gene testing methods were unable to detect this variant, but third-generation sequencing revealed the presence of the fusion gene. The study suggests that combining Hb capillary electrophoresis and third-generation sequencing can enhance the screening and diagnosis of Hb Lepore. This research provides valuable insights into the molecular characterization of thalassemia and its diagnosis in the Chinese population. [Extracted from the article]

A study conducted at the Thalassemia Center in Cipto Mangunkusumo Hospital in Indonesia found that thalassemia patients often experience zinc deficiency, which can lead to a decreased cellular immune response. The study aimed to evaluate the improvement of cellular immune response in splenectomized thalassemia major patients after zinc supplementation. However, the results showed that zinc supplementation did not have a significant effect on the cellular immune response in these patients. The researchers concluded that the effect of zinc supplementation on cellular immune response in splenectomized thalassemia major patients has not been proven yet. [Extracted from the article]

A recent study from McGill University Health Center in Montreal, Canada, explores the association between pediatric acute promyelocytic leukemia (APL) and Fanconi anemia (FA). A 4-year-old boy with APL was found to have biallelic pathogenic variants in the FANCD1/BRCA2 gene, confirming a diagnosis of FA-D1. The study also identified four additional patients with APL/FA, suggesting a possible link between these rare disorders. The research discusses the practical management of APL in the context of FA-D1 and provides an overview of current evidence and knowledge gaps. [Extracted from the article]

A recent report from Mahidol University discusses the findings of a study on thalassemia, a common genetic disease. The study focused on cognitive impairment and hippocampal neuronal damage in b-thalassemia mice. The researchers found that b-thalassemia mice exhibited decreased motor function and impaired learning and memory. These cognitive impairments were correlated with various intrinsic factors of thalassemia, including iron overload and damaged red blood cells. The study emphasizes the importance of blood transfusion and iron chelation in thalassemia patients and suggests that cognitive function assessments should be included in routine follow-up care. [Extracted from the article]

New research from Children's Hospital Philadelphia explores the use of luspatercept, a recently approved drug, in treating beta-thalassemia (BT) patients. While luspatercept has shown positive results in improving anemia and reducing the need for blood transfusions, not all patients experienced the expected increase in hemoglobin levels. The study suggests that combining luspatercept with another drug, TMPRSS6-ASO, may improve both erythroid and iron parameters in BT patients. These findings provide pre-clinical support for further investigation into the combination therapy. [Extracted from the article]

A recent study conducted by the Department of Hematology Oncology has shed light on a neurodevelopmental disorder called Nabais Sa-de Vries syndrome (NSDVS) and its connection to thalassemia. NSDVS is caused by mutations in the SPOP gene, and the study presented a case of a four-year-old girl with NSDVS and thalassemia, along with microcytic hypochromic anemia. This concurrence of genetic mutations and hematological manifestations has not been reported before, highlighting the need for further research to understand the underlying mechanisms and disease progression. The study was published in Clinical Pediatric Hematology-Oncology and can be accessed for free. [Extracted from the article]